Mr. James Clark has over 30 years experience in the fields of Pharmaceutical Delivery Systems Licensing and Business Development, Medical Device Development and Manufacturing, and the Development and Manufacturing of Polymeric Coatings.
In 1992 Mr. Clark founded Pharma Delivery Systems Inc. (PDS). PDS identified, negotiated and closed more than 25 licensing and development agreements in the areas of oral sustained release tablets, transdermal delivery systems, needle-free injector devices and solubility enhancement technologies, with companies such as Lilly, Smith Kline Beecham (including Paxil CR, and Requip), G.D.Searle, Roche, Abbott (Zyflo), Warner Lambert and Becton Dickinson.
Mr. Clark served on the Board of Directors of Antares Pharma (AIS NYSE-AMEX) between the years 2001-2005, and as an Executive Board member of the Third Pharmaceutical Achievement Awards in 2004.
Prior to creating PDS, Mr. Clark held positions as Head of Polymer/Coatings Manufacturing for an International Automotive Upholstery Leather producer, and Head of the U.S. subsidiary of a European Medical Device manufacturer. He also served in the U.S. Navy before starting his business career. He is a graduate of St Joseph’s University in Philadelphia (PA).
Dr. Alan Cookson is a co-founder of the Company. He brings substantial experience of the pharmaceutical industry both from his career in the Ares-Serono group in Europe and the United States where he held positions of increasing responsibility including VP, Research and Bus Development, and as founder and CEO of two start-up companies. Until recently Alan specialised in encouraging and managing the commercial exploitation of academic research innovation, and led a number of life sciences licensing projects for the University of Geneva, including the project that led to the formation of Apidel.
Prof. Robert Gurny is co-founder of the Company and co-inventor of the technologies, previously Professor at University of Geneva, he served as President of the Department of Pharmaceutical Sciences. Robert enjoys an outstanding reputation as a drug delivery scientist who brings a lot of realism to his creativity and has successfully managed many substantial industry/university collaborations with mid-cap and big pharma. He is also the author of more than 200 peer reviewed articles, several books and more than 80 abstracts of presentations as well as the inventor of over 40 patent applications. Robert has received numerous prestigious awards such as the Merck Award (1994), the APV Prize (1995), the Phoenix Award (1996) and the Roger Barré prize (1999). For many years Robert was the Editor-in-Chief of the European Journal of Pharmaceutics and Biopharmaceutics.
Dr. Rainer Hoffmann joined the Lohmann Group in 1979. Realising the potential for transdermal delivery systems he immediately set to work at developing a nitroglycerin drug delivery patch, launched in 1983. In 1984, the Lohmann group spun out the transdermal division under the name Lohmann Therapie System (LTS), of which Dr. Hoffmann became CEO and Chairman of the Executive Board. Today, LTS is one of the world leaders in the design, development and manufacturing of transdermal drug products. In late 2011 Dr. Hoffmann retired from LTS and started a private equity activity geared toward start-up biopharma companies. Dr. Hoffmann has also been Chairman of the Supervisory Board of SCS Skin Care Systems GmbH (Andernach, Germany), Smartrix Technologies Inc. (Canada), IKP- Institut für Klinische Pharmakologie Bobenheim Prof. Dr. Lücker GmbH (Grünstadt, Germany), ECS Environment Care Systems GmbH (Andernach, Germany) and CRS Clinical Research Services Andernach GmbH (Andernach, Germany) and was a Member of the Board of Directors of LAB International SRL (Barbados).
Dr. Vincent Lenaerts has a track record as a successful entrepreneur in the bio-pharmaceutical industry creating shareholder value in all four companies he co-founded or managed, including Europeptides in France, Labopharm, Bioxalis and Miraculins in Canada; lastly he was VP Bus Dev for UCB, based in the UK; he is the recipient of the 1999 J-Armand Bombardier award for commercially-successful technological innovations.
Dr. Michael Möller is co-founder of the Company and co-inventor of the technologies; he is an organic research chemist with extensive international experience gathered at Philips University, Marburg, Germany, Okayama University of Science, Japan, Stanford University, USA and the IBM Almaden Research Center, USA; Michael’s expertise in designing, characterizing and synthesizing novel molecules both with specific material applications and for assimilation into useful nanostructures led him to join the School of Pharmacy of the University of Geneva where pioneering work on novel molecules and structures as drug delivery mechanisms has been made. The combination of expertise in chemistry, synthesis and practical application in drug delivery has enabled the establishment of key intellectual property leading directly to the formation of Apidel.